Great collaboration and fantastic support by ESMO - Eur. Oncology!

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Maybe the difference lies in whether the low-confidence residues are close to other residues, where they more likely could have a pathogenic effect, or they are far apart, as seen above. In any case, I would recommend checking the AF structure & pDLLT when interpreting AM scores!

Today, NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma . Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators MGH Neurosurgery and Mass General Cancer Center!
nej.md/3VnjUIq

This is wild. The first sentence of the paper. Everyone involved needs to be let go. ScienceDirect The point of scientific publishing has completely been lost. sciencedirect.com/science/articl…

sciencedirect.com/science/articl… Let’s try it with this link! #LCSM The ROS1ders, Inc. RosesfromaRos1der Updates on OS by Sebastian Michels on our #EUCROSS trial. Great work!

Big kudos to Sebastian Michels for publishing OS updates of our #EUCROSS trial for #NSCLC patients harboring #ROS1 aberrations. The ROS1ders, Inc. #LCSM
authors.elsevier.com/sd/article/S20…

Osimertinib vs Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant NSCLC

'Up-front treatment with osimertinib was associated with a lower risk of brain progression vs the sequential approach (hazard ratio, but a comparable OS was observed between both strategies (HR, 1.01)…

Der Deutsche Krebshilfe Preis 2023 geht an die Kölner Professoren Reinhard Büttner, Jürgen Wolf und Roman Thomas. Auszeichnung insbesondere für ihre Arbeit im interdisziplinären ‘Nationalen Netzwerk Genomische Medizin (nNGM) – #Lungenkrebs ’. nNGM uk-koeln.de/uniklinik-koel…

Mal was Neues! Im ChatGPT-Store findet man auch Unseren Bot. Orientiert sich natürlich an den Videos (trainiert an den Transkripten). Ist erst am Anfang (haben erst wenige Texte hochgeladen), wird aber besser werden - gerne mal austesten!

Courtesy of Chul Kim we thought this might be featuring on a few of our members' Xmas wish lists.
Happy festive season everyone and enjoy a well-deserved break!
#LCSM

Impact of TP53 mutations in squamous NSCLC? Retrospective analysis Clinical Lung Cancer of 220 pts showed TP53mt subset had better mOS with immunotherapy (24.7m vs 12.0m) and longer mPFS (9.6m vs 3.2m) vs TP53wt. No differences in chemotherapy outcomes.

clinical-lung-cancer.com/article/S1525-…

In KRAS G12Cmut NSCLC 🫁 we have reached a plateau in outcome w/KRAS G12C inh (~ safety). Intracranial RR🧠 and activity regardless of co-mutations may make difference btw them. Hwvr, in the future🔮, will we use KRAS inhibitors for each KRASmut subtype or panRAS inh? #ESMOAsia23

sciencedirect.com/science/articl… First real-world evaluation of nNGM as compared to SOC in #germany out! Big kudos to all colleagues involved! Still more to come! #LCSM

Wichtiger Baustein auf dem Weg zum #HIV -Impfstoff: Forschende der #Uniklinik #Köln haben die HIV-Antikörperantwort bei über 2.300 Patienten untersucht und verschiedene Faktoren identifiziert, die zur natürlichen Bildung neutralisierender Antikörper führen. uk-koeln.de/uniklinik-koel…

🩸 The cheapest liquid biopsy you will see at #ISLB23 😉
🧬 KIF5B-RET fusion stage IV lung adenocarcinoma patient treated with chemo-immunotherapy first, and selpercatinib in 2nd line. You can guess when selpercatinib was initiated by following the CEA levels. #LCSM

Proud to see our figure 1 on KEAP1/NFE2L2 transcription signatures made it to the cover of ⁦JTO & JTO CRR⁩ current issue. #LCSM #KEAP1

uk-koeln.de/uniklinik-koel…

#ESMO23 truly delivered on the ESMO promise to stand by the side of oncologists & make a difference in the lives of people with cancer. Many thanks to all of you who made this happen and see you in Barcelona for #ESMO24 .
ow.ly/u6IX50Q0U3p

silke gillessen Andres Cervantes

#ESMO23 was a great congress and a excellent opportunity for ISLB to meet our members and new ones! #liquidbiopsy is a very dynamic field and certainly our society is contributing in education and policy. Join us in Madrid in November 19-21 for #ISLB23
International Society of Liquid Biopsy ESMO - Eur. Oncology